Author
Listed:
- Camélia Benlabiod
(INSERM, UMR 1287, Gustave Roussy
Université Paris-Saclay, UMR 1287, Gustave Roussy
Gustave Roussy, UMR 1287)
- Maira da Costa Cacemiro
(INSERM, UMR 1287, Gustave Roussy
Université Paris-Saclay, UMR 1287, Gustave Roussy
Gustave Roussy, UMR 1287
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo-USP)
- Audrey Nédélec
(Ludwig Institute for Cancer Research
de Duve Institute, Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Université catholique de Louvain)
- Valérie Edmond
(INSERM, UMR 1287, Gustave Roussy
Université Paris-Saclay, UMR 1287, Gustave Roussy
Gustave Roussy, UMR 1287)
- Delphine Muller
(INSERM, UMR 1287, Gustave Roussy
Université Paris-Saclay, UMR 1287, Gustave Roussy
Gustave Roussy, UMR 1287)
- Philippe Rameau
(Integrated Biology Core Facility, Gustave Roussy)
- Laure Touchard
(Unité Mixte de Service AMMICA 3655/US 23, Gustave Roussy)
- Patrick Gonin
(Unité Mixte de Service AMMICA 3655/US 23, Gustave Roussy)
- Stefan N. Constantinescu
(Ludwig Institute for Cancer Research
de Duve Institute, Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Université catholique de Louvain)
- Hana Raslova
(INSERM, UMR 1287, Gustave Roussy
Université Paris-Saclay, UMR 1287, Gustave Roussy
Gustave Roussy, UMR 1287)
- Jean-Luc Villeval
(INSERM, UMR 1287, Gustave Roussy
Université Paris-Saclay, UMR 1287, Gustave Roussy
Gustave Roussy, UMR 1287)
- William Vainchenker
(INSERM, UMR 1287, Gustave Roussy
Université Paris-Saclay, UMR 1287, Gustave Roussy
Gustave Roussy, UMR 1287)
- Isabelle Plo
(INSERM, UMR 1287, Gustave Roussy
Université Paris-Saclay, UMR 1287, Gustave Roussy
Gustave Roussy, UMR 1287)
- Caroline Marty
(INSERM, UMR 1287, Gustave Roussy
Université Paris-Saclay, UMR 1287, Gustave Roussy
Gustave Roussy, UMR 1287)
Abstract
Somatic mutations in the calreticulin (CALR) gene are associated with approximately 30% of essential thrombocythemia (ET) and primary myelofibrosis (PMF). CALR mutations, including the two most frequent 52 bp deletion (del52) and 5 bp insertion (ins5), induce a frameshift to the same alternative reading frame generating new C-terminal tails. In patients, del52 and ins5 induce two phenotypically distinct myeloproliferative neoplasms (MPNs). They are equally found in ET, but del52 is more frequent in PMF. We generated heterozygous and homozygous conditional inducible knock-in (KI) mice expressing a chimeric murine CALR del52 or ins5 with the human mutated C-terminal tail to investigate their pathogenic effects on hematopoiesis. Del52 induces greater phenotypic changes than ins5 including thrombocytosis, leukocytosis, splenomegaly, bone marrow hypocellularity, megakaryocytic lineage amplification, expansion and competitive advantage of the hematopoietic stem cell compartment. Homozygosity amplifies these features, suggesting a distinct contribution of homozygous clones to human MPNs. Moreover, homozygous del52 KI mice display features of a penetrant myelofibrosis-like disorder with extramedullary hematopoiesis linked to splenomegaly, megakaryocyte hyperplasia and the presence of reticulin fibers. Overall, modeling del52 and ins5 mutations in mice successfully recapitulates the differences in phenotypes observed in patients.
Suggested Citation
Camélia Benlabiod & Maira da Costa Cacemiro & Audrey Nédélec & Valérie Edmond & Delphine Muller & Philippe Rameau & Laure Touchard & Patrick Gonin & Stefan N. Constantinescu & Hana Raslova & Jean-Luc , 2020.
"Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN,"
Nature Communications, Nature, vol. 11(1), pages 1-15, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18691-3
DOI: 10.1038/s41467-020-18691-3
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18691-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.